Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Angiodynamics (ANGO) Common Equity (2016 - 2025)

Angiodynamics (ANGO) has disclosed Common Equity for 15 consecutive years, with $176.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity fell 5.59% year-over-year to $176.3 million, compared with a TTM value of $176.3 million through Nov 2025, down 5.59%, and an annual FY2025 reading of $183.0 million, down 11.0% over the prior year.
  • Common Equity was $176.3 million for Q4 2025 at Angiodynamics, down from $178.9 million in the prior quarter.
  • Across five years, Common Equity topped out at $454.9 million in Q1 2021 and bottomed at $176.3 million in Q4 2025.
  • Average Common Equity over 5 years is $328.8 million, with a median of $399.4 million recorded in 2023.
  • The sharpest move saw Common Equity rose 3.32% in 2023, then crashed 54.05% in 2024.
  • Year by year, Common Equity stood at $432.4 million in 2021, then decreased by 5.65% to $408.0 million in 2022, then fell by 1.65% to $401.2 million in 2023, then plummeted by 53.45% to $186.8 million in 2024, then decreased by 5.59% to $176.3 million in 2025.
  • Business Quant data shows Common Equity for ANGO at $176.3 million in Q4 2025, $178.9 million in Q3 2025, and $183.0 million in Q2 2025.